Heart failure & cardiomyopathies
Impact of a Novel Wearable Sensor on Heart Failure Rehospitalization: An Open-Label Concurrent-Control Clinical Trial
Main finding · HF hospitalizationResult — go to the resultHazard ratio 0.62Authors' conclusion
In patients with a recent HF hospitalization, a strategy of using HFMS data for HF management is associated with a 38% relative risk reduction in 90-day HF rehospitalization.
Study context
- Population
- Patients discharged within the previous 10 days after HF hospitalization, with a HF event in the previous 6 months
- Participants
- 522 patients93 sites
- Comparison
- HFMS-guided HF management vs usual care
- BMAD-TXn = 249
- BMAD-HFn = 245reference
- Outcome
- Time to first HF hospitalization
- Follow-up
- Up to 90 days
Methodological detailsopen-label intervention arm, multicentre (93 sites)
- Open-label intervention arm
- Multicentre (93 sites)
Main finding
HF hospitalization
Hazard ratio
0.62
P = 0.03
As reported in the abstract
Further findings
All hospitalizations (both arms combined) · up to 90 days
- Hospitalizations in 189 subjects
- 276
- HF-related hospitalizations in 82 subjects
- 108
Original publication
Impact of a Novel Wearable Sensor on Heart Failure Rehospitalization: An Open-Label Concurrent-Control Clinical Trial. JACC Heart Fail. Published 9 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →